Main Article Content
Background Sepsis-associated cholestasis (SAC) is an intrahepatic cholestasis caused by inflammatory cytokines. Patients with this condition have poor prognoses. Antibiotics are the mainstay of therapy, however, other adjuvant therapies, such as ursodeoxycholic acid (UDCA), have not been well established.
Objective To assess the effect ofUDCA for treatment ofneonatal sepsis-associated cholestasis.
Methods We performed a randomized, double-blind, controlled trial in 3 7 neonates who were diagnosed with sepsis-associated cholestasis in the Neonatal Care Unit of Cipto Mangunkusumo Hospital. Subjects were divided into two groups, with 19 neonates randomly allocated to the intervention group (received UDCA at 30 tngikg/day divided into 3 doses for 7 days) and 18 neonates to the control group (received placebo) . After 7 days of treatment, we evaluated the subjects' liver function parameters and performed a
Results Liver function parameter improvements at day 7 were not significantly different between the UDCA group and the control group, including for mean decrease of total bilirubin (TB) levels [2.2 (SD 2.9) mg/dL vs 1.7 (SD 4.6) mg/dL; P=0.080), mean decrease of direct bilirubin (DB) levels [1.1 (SD 2.3) mg/dL vs 0.6 (SD 3.6) mg/dL; P=0.080), median indirect bilirubin (lB) levels [0.4 (range 0.1- 5.6) mg/dL vs 0.9 (range 0.1-4.1) mg/dL; P=0.358) , mean decrease of alanine aminotransferase (ALT) levels [0.5 (-80.0 -
21.0) U/L vs -2.0 (ranged -167 .0 - 85.0) U/L; P= 0.730), median aspartate aminotransferase (AST) levels [ 43 .0 (range 14.0-297 .0) U/L vs 150.0 (range 24.0-840.0) U/L; P=0.081), and median gamma-glutamyl transpeptidase (GGf) levels [125.0 (48.0-481.0) U/L vs 235.0 (56.0-456.0) U/L; P=0.108)). Five neonates in control group died compared to two in the UDCA group (P=0.232). In addition, UDCA did not significantly lengthen the survival time (hazard ratio/HR 3.62; 95%CI 0.69 to 18.77) .
Conclusion Ursodeoxycholic acid tends to improve total bilirubin, direct bilirubin, and AST levels in sepsis associated cholestasis .
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Cardillo J, Pinsky MR. Epidemiology of severe sepsis in United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-10.
3. Bachtiar KS, Oswari H, Batubara JRL, Amir I, Latief A, Firman K. Cholestasis sepsis at neonatology ward and neonatal intensive care unit Cipto Mangunkus umo Hospital 2007: incidence, mortality rate and associated risk factors. MedJ Indones. 2008;17:107-13.
4. Chand N, Sanyal AJ. Sepsis-induced cholestasis. Hepatology. 2007 ;45 :230,41.
5. Bolder U, Ton-Nu HT, Schteingart CD, Frick E, Hofmann AF. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology. 1997; 112:214-25.
6. Whiting JF, Green RM, Rosenbluth AB, Golian JL. Tumor necrosis factor-alpha decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis. Hepatology. 1995;22:1273-8.
7. Gilroy RK, Mailliard ME, Golian JL. Gastrointestinal disorders of the critically ill. Cholestasis of sepsis. Best Pract Res Clin Gastroenterol. 2003;17:357-67.
8. Ng VL, Balistreri WF. Treatment options for chronic cholestasis in infancy and childhood. Curr Treat Options Gastroenterol. 2005;8:419-30.
9. Beuers U. Drug insight: mechanisms and sited of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:318-28.
10. Oswari H. Mekanisme peran asam ursodeoksikolat terhadap kolestasis terkait sepsis. [dissertation]. Jakarta: Universitas Indonesia; 2008.
11. Benitz WE. Adjunct laboratory tests in the diagnosis of early onset
neonatal sepsis. Clin Perinatol. 2010;37:421-38.
12. Heil W, Koberstein R, Zatwa B. Reference ranges for adults and children. Mannheim: Roche Diagnostic GmbH; 2004.
13. Tufano M, Nicastro E, Giliberti P, Vegnente A, Raimundi F, Iorio R. Cholestasis in neonatal intensive care unit: incidence, aetiology and management. Acta Paediatr. 2009;98:1756-61.
14. Shamir R, Maayan-Metzger A, Bujanover Y, Ashkenazi S, Dinari G, Sirota L. Liver enzyme abnormalities in gram negative bacteremia of premature infants. Pediatr Infect Dis J. 2000;19:495-8.
15. Tiker F, Tarcan A, Kilicdag H, Gurakan B. Early onset conjugated hyperbilirubinemia in newborn infants. Indian J Pediatr. 2006;7 3:409- 12.
16. Rohsiswatmo R. Kontroversi diagnosis sepsis neonatorum. In: Hegar B, Trihono PP, Ifran EB, editors. Update in neonatal infection. Jakarta: Departemen Ilmu KesehatanAnak FKUI RSCM; 2005. p. 32-43.
17. Oswari H, Widjaja RK, Rohsiswatmo R, Cleghorn G. Prognostic value of biochemical liver parameters in neonatal sepsis-associated cholestasis. J Paediatr Child Health. 2013 ;49:E6-11.
18. Maldonado SR, Tellez NCG, Yescas-Buendia G, FernanCarrocera LA, Echaniz-Aviles OL, Rios ERR. Effectiveness of ursodeoxycholic acid vs phenobarbital for the treatment of neonatal cholestasis: a cross-randomized clinical trial. Bol Med Hosp Infant Mex. 2010;67:418-23.
19. Al-Hathlol K, Al-Madani A, Al-Salf A, Abulaimon B, Al-Tawil K, El- Demerdash A. Ursodeoxycolic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants. Singapore Med J. 2006;47:147-51.